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Summary
The traditional view of atherosclerosis as a pathological lipid
deposition within the artery wall has been redefined by a more
complex concept of an ongoing inflammatory disease. 
The atherosclerotic process is initiated when cardiovascular
risk factors, through a chemical, mechanical or immunological
insult, activate and/or injury the endothelium, thus contribut-
ing to endothelial dysfunction and fragmentation. This trig-
gers a cascade of inflammatory reactions, in which monocytes,
macrophages, T lymphocytes, vascular smooth muscle cells
actively participate. Particularly, atherosclerotic lesions have
been seen to have increased expression of T helper-1 cells to-
gether with increased levels of the T helper-1 related pro-inflam-
matory cytokines. Along with pro-inflammatory cytokines, other
molecular factors involved in atherosclerosis appearance, pro-
gression and complication include chemokines, growth factors,
vasoactive substances, enzymes, apoptosis signals and many
others. Many of these molecular factors are both involved as
possible markers of the atherosclerotic disease activity and
burden, but may also play a crucial role in the pathogenesis of
the disease. In recent years, the discovery of progenitor cells of
myeloid origin has offered the prospect of merging the most re-
cent theories on the pathogenesis of atherosclerosis with the
evolving concept of a role of these progenitor cells in the repair
of the injured vessel wall and the neovascularisation of is-
chemic tissues. This review summarizes current knowledge
about the biology of atherosclerosis with emphasis on the
mechanisms of endothelial damage and repair and on the con-
cept that the turnover and replacement of endothelial cells is a
major determinant in the maintenance of vascular integrity.
KEY WORDS: lipoproteins, inflammation, endothelial dysfunction, microparti-
cles, progenitors.
Introduction
Atherosclerosis is a multifactorial disease that involves chronic
inflammation from initiation to progression (1, 2), and all its risk
factors contribute to atherosclerosis pathogenesis by aggravat-
ing the underlying inflammatory process (1, 2).
Molecular determinants of atherosclerosis appearance, pro-
gression and complication are numerous and very often over-
lap, in that the same factors that contribute to atherosclerosis
initiation may also have a crucial role in the plaque growth and
rupture. Molecular risk factors, like elevated plasma lipids and
glucose levels, represent major risk factors for atherosclerosis
and cardiovascular disease (3, 4); the latter risk factors have
been implicated in atherosclerosis appearance and progres-
sion by starting a cascade of molecular events leading to
plaque instability and cardiovascular events (1, 2). Even non-
molecular risk factors, like hypertension, aging, smoking,
through the action of molecular intermediates of the inflamma-
tion-oxidation balance, are major contributors to the pathogen-
esis of atherosclerosis. Along with cardiovascular risk factors,
many other molecular players have a role in the atherosclerotic
process. Inflammatory cytokines (1, 2), markers of oxidative
burden (5), growth factors (6, 7), apoptosis signals (8), media-
tors of vascular tone (9), have all a pivotal influence on athero-
sclerosis evolution.
The appreciation of the role of all these molecular mediators of
the atherosclerotic disease provides a mechanistic framework
to understand more deeply about the atherosclerosis epidemic
and the clinical benefits of newer therapeutic strategies in re-
ducing the burden of atherosclerosis complications.
Lipids and atherosclerosis initiation and progression
The atherosclerotic process is initiated when lipid-containing
lipoproteins accumulate in the intima and activate the endothe-
lium (1, 2) (Figure 1). Thereafter, an inflammatory response oc-
curs, which is characterised by recruitment of circulating leuko-
cytes and the production of growth factors which encourage
cell migration and proliferation (1, 2).
Studies in animal models showed that arterial retention of
lipoproteins is regulated by the balance of delivery versus ef-
flux (10-12). Delivery appears to be dependent on lipoprotein
concentration, lipoprotein size, and the integrity of the endothe-
lium. Particularly, delivery increases for higher plasma lipid lev-
els and for smaller lipoproteins, like LDL, small dense LDL and
triglyceride-rich lipoprotein remnants. All lipoproteins, apart
from nascent triglyceride rich lipoproteins, penetrate and infila-
trate the arterial wall (10, 11, 13, 14). 
It has been also observed a significant inverse relation be-
tween lipoprotein diameter and fractional loss from the intima
(15). The fractional loss of lipoproteins from the intima may be
a combination of efflux of macromolecules from the intima-in-
ner media into the vascular lumen and degradation of lipopro-
teins by the cells in the intima-inner media. It has been also ob-
served (16) that the lipoprotein fractional loss may be also due
to lipoproteins that were irreversibly attached to arterial wall
components, most likely glycosaminoglycans.
The infiltration and retention of lipoproteins in the arterial intima
initiate an inflammatory response in the artery wall (17, 18). In-
deed, modification of retained lipoproteins contribute to the re-
lease of phospholipids that can activate endothelium (18). That
is the basis for increased expression of adhesion molecules
and inflammatory genes by endothelial cells and for the loss of
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the morpho-functional integrity of the endothelium, that is also
named endothelial dysfunction.
Endothelial dysfunction is today believed one of the most im-
portant initial steps of the atherosclerosis process (19), and
most cardiovascular risk factors, including dyslipidemia, have
been implicated in its appearance (20). We have found that
hypercholesterolemic as well as hypertriglyceridemic patients
have an impaired endothelial function that may be partially re-
versed by statin or fibrate therapy (21, 22). We also found
that oxidized LDL may have a role in impairing endothelial
function (23). More recently, we have demonstrated that pa-
tients with primary hypercholesterolemia have an increased
endothelial damage, as demonstrated by an elevated plasma
concentration of endothelial microparticles (24). These data
strongly suggest that dyslipidemias contribute to a significant
extent to endothelial damage and initiation of the atheroscle-
rosis process.
Other than endothelial dysfunction, early atherosclerosis is
characterized by reduced large artery distensibility. 
A few studies (25, 26) have reported conflicting data on the
influence of high plasma cholesterol levels on reduced arteri-
al elasticity, a novel marker of early atherosclerosis and pre-
mature coronary heart disease risk (27). Some studies found
patients with hypercholesterolemia have stiffer blood vessels
than matched controls (26) and that cholesterol reduction
may have a role in reducing large artery stiffness (28). Other
authors reported an increased aortic distensibility in subjects
with heterozygous familial hypercholesterolemia (25), an in-
verse association between cholesterol and aortic stiffness
(29), as well as unchanged or increased arterial stiffness after
cholesterol-lowering therapy (30, 31). We demonstrated that
despite a role for hypercholesterolemia to favour arterial stiff-
ening, inflammation seem to play a major influence on arterial
distensibility regardless of other cardiovascular risk factors
(32). Interestingly, both short-term low-cholesterol/low-satu-
rated fat diet (33) and statin therapy (28) in hypercholestero-
laemia may be effective in improving large artery stiffness,
most likely through the reduction of plasma cholesterol levels
but also through the mitigation of low-grade systemic inflam-
mation.
Inflammation: a major mediator of atherosclerosis
The accumulation of lipids within the artery wall may initiate an
inflammatory process in the artery. However, other major risk
factors have been observed to contribute to the activation of a
low-grade systemic inflammatory reaction (1, 2). Diabetes,
smoking, hypertension, hypoalphalipoproteinemia and other
risk factors have been associated with increased plasma levels
of several biomarkers of inflammation (34-37). Interestingly, all
these risk factors may contribute to endothelial activation and
dysfunction (Figure 2). Activated endothelial cells express on
their luminal surface leukocyte adhesion molecules, which
cause white blood cells adhesion on the vascular surface at
sites of activation. Once the white blood cells have attached,
chemokines produced in the underlying intima stimulate them
to migrate into the subendothelial space (1, 2). Monocytes en-
tered the intima differentiate into macrophages and express at
high level scavenger receptors and toll-like receptors. Scav-
58 Clinical Cases in Mineral and Bone Metabolism 2008; 5(1): 57-62
E. Mannarino et al.
Figure 1 - Mechanisms of lipoprotein mediated atherogenesis. Intermediate size lipoproteins (grey circles) are those that are preferentially retained in-
to the artery wall and activate the atherosclerosis cascade. Small size lipoproteins (black circles) infiltrate the artery wall, but may be also cleared
away from the artery. WBCs: white blood cells.


















enger receptors may contribute to internalize apoptotic cell
fragments, oxidized LDL particles and other detrites. Lipid de-
position into macrophages contribute to  foam cell formation.
Toll-like receptors can initiate a signal cascade that leads to
macrophage activation and production of inflammatory cy-
tokines, proteases, and cytotoxic radical molecules (1, 2). Also
T-lymphocytes infiltrate the atherosclerotic lesions. These T-
cells recognize antigens presented to them by activated
macrophages. Activated T cells therefore differentiate mainly
into T-helper 1 cells and begin producing interferon-gamma,
which in turn increases the process of antigen presentation by
macrophages to lymphocytes and stimulates synthesis of other
cytokines like tumor necrosis factor and interleukin-1. All these
cytokines stimulate the production of many other inflammatory
and cytotoxic molecules thus increasing the burden of the in-
flammatory reaction.
The demonstration that all these events linked to the inflamma-
tion process within the artery may contribute to atherosclerosis
development come from several lines of evidence.
First, inflammatory cells are present in atherosclerotic lesions
at all stages of development, exhibit activation markers and are
particularly prominent at sites of plaque rupture (38). Second,
adoptive transfer of purified CD4+ T cells from oxLDL-immu-
nized mice accelerates atherosclerosis (39) and the absence of
CD4+ cells in apoE KO mice leads to reduced atherosclerosis,
indicating that CD4+ cells constitute a major proatherogenic
cell population (40). Third, patients with clinically relevant in-
flammatory diseases like rheumatoid arthritis develop early ath-
erosclerosis (41-43). Fourth, even low-grade systemic inflam-
mation may be associated with premature atherosclerosis de-
velopment (32,33). Finally, several markers of inflammation
have been prospectively associated with an increased risk of
the most typical complications of atherosclerosis, including is-
chemic heart disease events (44, 45).
We have found that young to middle aged patients with rheuma-
toid arthritis with low disease activity, free from cardiovascular
risk factors and overt cardiovascular disease, have an altered
endothelial reactivity that seems to be primarily related to the
disease associated chronic inflammatory condition (41). Circu-
lating CD4+CD28(null) lymphocytes are increased in rheuma-
toid arthritis (46). Patients with persistent CD4+CD28(null) cell
expansion show preclinical atherosclerotic changes, including
arterial endothelial dysfunction and carotid artery wall thicken-
ing, more significantly than patients without expansion (42).
These findings suggest a contribution of this cell subset in
atheroma development in rheumatoid arthritis.
Although rheumatoid arthritis represent an independent risk
factors for atherosclerosis, this may be confounded by continu-
ous pharmacologic treatment. Primary Sjögren’s syndrome
shares several features of this disease and therefore repre-
sents an interesting model for verifying the presence of accel-
erated atherosclerosis in the absence of pharmacologic inter-
ference. We found that subclinical atherosclerosis was evident
in about one-half of the patients with Sjögren's syndrome (43).
Its association with some features typical of connective tissue
diseases, such as the presence of anti-SSA, suggests that the
immune dysregulation characterizing this autoimmune disorder
may play a key role in inducing early atherosclerosis (43).
Interestingly, in all these clinical settings caractherized by an
exaggerated activation of the inflammation cascade, an associ-
ation between humoral markers of inflammation and vascular
damage has been found. The same correlation has been often
found in other settings which are caractherized by a low-grade
inflammatory cascade activation. Accordingly, increased plas-
ma C-reactive protein (CRP) and inflammatory cytokine levels
have been associated with endothelial dysfunction, arterial stiff-
ness and arterial intima-media thickness in patients carrying
one or more cardiovascular risk factors. However, it is impor-
tant to underline that, even in apparently healthy subjects, the
presence of elevated plasma levels of acute phase proteins
(i.e. CRP, fibrinogen) and cytokines (i.e. interleukin-6) is asso-
ciated with an increased risk of future cardiovascular events
(44, 45). We have found that plasma CRP levels may provide
independent information on ischemic heart disease risk mainly
in middle-aged men and in the case of ischemic heart disease
events that occur relatively soon after the baseline evaluation
(44). It was also found that elevated plasma interleukin-6 con-
centrations are more strongly related to ischemic heart disease
risk than CRP and fibrinogen (45). An inflammation score
based on high plasma interleukin-6 and fibrinogen levels used
in combination with traditional risk factors may improve our
ability to adequately identify high risk individuals (45).
Mechanisms of vascular damage and repair
It is widely believed that cardiovascular risk factors promote
atherogenesis by damaging endothelium (Figure 2). Endothe-
lial status has been mainly assessed by focusing the attention
on the quantification of the endothelium capacity to modulate
arterial vasomotion (47). An alternative way to get information
on endothelial health is to measure products of endothelial cell
injury. Quantification of circulating endothelial cells has been
suggested as a method of assessing endothelial damage, giv-
en that exposure of the endothelium to most cardiovascular
risk factors may cause the detachment of endothelial cells from
the intimal monolayer, thus releasing mature endothelial cells
in peripheral blood (48). More recently, there has been consid-
erable interest in a novel marker of endothelial cell injury,
namely endothelial microparticles (EMPs) (49, 24). Microparti-
cles are small vesicles released from the membrane surface
during cell activation, injury, or apoptosis, and display the typi-
cal surface cell proteins and cytoplasmic components of their
cell origin. Endothelial cell vesiculation happens also under
physiologic condition, possibly as a mechanism of endothelial
cell renewal or cross-talk with other cellular targets. Elevated
levels of EMPs, mostly defined as CD31+/CD42- MPs, are
found in patients with a variety of vascular diseases and in sub-
jects exposed to cardiovascular risk factors (24). In the setting
of hypercholesterolemia, we had previously found that the
number of circulating CD31+/CD42- microparticles was associ-
ated with aortic stiffness and that microparticles from hypercho-
lesterolemic patients cause a significant impairment of en-
dothelial repair in vitro (24).
Under physiological conditions the integrity of the endothelial
monolayer is maintained by replication of adjacent cells (50);
however, in conditions of increased endothelial injury, regener-
ation of the injured endothelium may be assisted by endothelial
progenitor cells (EPCs) homing into the artery wall (50). Evi-
dence that EPCs contribute to endothelial cell regeneration
comes from animal studies and computer-based simulation
models in humans (51,52). In hypercholesterolemic apolipopro-
tein E knock-out mice, the systemic transfusion of EPCs signifi-
cantly improved endothelial dysfunction (51), whereas in hu-
mans, an EPCs homing rate of 5% per year was sufficient to
significantly delay defects in endothelial integrity (52).
Progenitors to vascular endothelial cells mainly reside in the
adult bone marrow, from where they can be mobilized into circu-
lation by cytokines and growth factor signals. EPCs are defined
by the expression of antigens indicating staminality, like CD133
and CD34, but also antigens that are typical of mature endothe-
lial cells, like VEGFR-2 or KDR (53). These progenitors are in-
volved in the process of repair of ischemic organs but also in the
repair of the injured endothelium. The endothelial repair is a
highly coordinated multi-step process that requires EPCs mobi-
lization into circulation, their migration in the vascular endotheli-
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um and finally their differentiation into mature and healthy en-
dothelial cells. Since it is very common to find a significant en-
dothelial injury in subjects with cardiovascular risk factors, it is
extremely important to know whether there is a relationship be-
tween cardiovascular risk factors and the number of circulating
endothelial progenitor cells (Figure 3). In this respect, we recent-
ly found that hypercholesterolemic patients have a reduced num-
ber of circulating EPCs compared to normolipidemic subjects
(24); and the same was also found in hypertensive patients com-
pared to healthy normotensive controls (54). However, not only
dyslipidemia and hypertension are typically characterized by a
reduced number of endothelial progenitors, but also other major
risk factors are today known to cause a significant EPCs loss,
thus reducing their potential to repair ischemic organs and the in-
jured endothelium. So, it is important to know why a reduced
number of endothelial progenitor cells is commonly found in sub-
jects at increased cardiovascular risk. Today we know that most
cardiovascular risk factors may contribute to reduce the number
of circulating EPCs (Figure 3) by reducing:
a. their initial maturation, expansion and mobilization from
the bone marrow;
b. their vitality and survival in the blood.
We found that, likewise mature endothelial cells, also EPCs
may be mechanically and functionally injured, thus releasing
microparticles (55). Particularly, we demonstrated that cultured
EPCs undergo extensive apoptosis and release a significant
amount of microparticles when exposed to a range of concen-
trations of the pro-apoptotic hydrogen-peroxide. In addition, we
found in human blood CD34+/KDR+ MPs, possibly indicating
that EPCs may be injured in the circulation, expecially in pa-
tients at increased cardiovascular risk, and may consequently
release MPs in vivo. Finally, we also found that, likewise mi-
croparticles from mature endothelial cells, also microparticles
from circulating EPCs may have an active role in the process
of vascular damage (55).
Although the new paradigm of risk factors induced EPCs loss is
now deeply ingrained in the scientific community, an understand-
ing of how some risk factors may contribute to the loss of circu-
lating EPCs remains only partially understood. Homeobox genes
encode for transcription factors, which regulate cell proliferation
and migration and play an important role in the development of
the cardiovascular system during embryogenesis (56, 57); these
genes were also involved in a differentiation-like process occur-
ring in normal adult cells and act as regulator genes that main-
tain tissue or organ specificity in the adult body (56, 57). Home-
obox A9 (HOXA9) is a member of the homeobox gene family
and a number of possible target genes of HOXA9 in human
CD34+ cells were recently identified (58). By modulating down-
strem target genes HOXA9 contributes in physiological condi-
tions to endothelial commitment of EPCs, post-natal neovascu-
larization and injured endothelium repair (59-61). HOXA9 over-
expression is associated with an increased number of EPCs,
while in HOXA9 deficient mice there is a lower number of EPCs
and impaired postnatal neovascularization after ischemia (61).
We found that downregulation of HOXA9 expression in peripher-
al CD34+ cells may have a role in the loss of circulating EPCs,
thus potentially impairing postnatal neovascularization and vas-
cular repair.
Conclusions
The lesions of atherosclerosis represent a series of highly spe-
cific cellular and molecular responses. This multi-step process
of vascular injury under cardiovascular risk exposure, activa-
tion of local and systemic inflammation, vascular cells senes-
cence and apoptosis and contribution of progenitor cells to vas-
cular repair is higly regulated by key molecular signals. Thus,
translating this molecular knowledge to interventional cardio-
vascular medicine, such a detailed understanding in the com-
plex regulation of atherosclerosis development and progres-
sion may be helpful for more effectively preventing the many
clinical consequences which parallel the complication of vulner-
able atherosclerotic plaques.
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